Table 4. Clinical and pathological features of breast cancer patients according to their age.
Features | Postmenopausal | Young | |
---|---|---|---|
n=27 | n=41 | p | |
Age at diagnosis, median (range), years | 61 (55-74) | 32 (23-35) | |
Tumor Subtype | |||
Luminal A | 8 (8) | 2 (4.9) | 0.04 |
Luminal B | 14 (51.9) | 19 (46.3) | |
Luminal | 2 (7.4) | 4 (9.8) | |
HER2+ | 1 (3.7) | 5 (12.2) | |
Triple Negative | 2 (7.4) | 10 (24.4) | |
Not Determined | 0 | 1 (2.4) | |
Clinical Stage, n (%) | |||
I/II | 19 (73.1) | 23 (65.7) | 0.539 |
III/IV | 7 (26.9) | 12 (34.3) | |
BRCA germline status | |||
BRCA1/BRCA2 mut | 2 (7.4) | 6 (14.6) | 0.365 |
BRCA1/BRCA2 wt | 25 (92.6) | 35 (85.4) | |
PIK3CA somatic status | |||
PIK3CA path mut | 10 (37) | 7(17.1) | * |
PIK3CA wt | 17 (63) | 34 (82.9) | |
Luminal Tumors vs PIK3CA somatic status | |||
Luminal PIK3CA mut | 8 (33.3%) | 5 (20%) | 0.291 |
Luminal PIK3CA wt | 16 (66.7%) | 20 (80%) |
Tumor Subtype based on ER, PR, HER2 and Ki67 expression, as described in methods. Missing data were not computed. Pearson's chi-Square. *not tested owing to the small sample size.